Ascendis Pharma LLC
FDA inspection history in Palo Alto, California, 2026
- 1
- Form 483
Every document, by year
- Form 483
2026: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2026One Form 483, at Palo Alto, California.
Cited most
Across all Ascendis Pharma observations on file
- 21 CFR 314.80(c)(1)(i)Postmarketing reporting of adverse drug experiences1
- 21 CFR 600.80(b)Postmarketing reporting of adverse experiences1
The complete Ascendis Pharma file.
All 1 documents as original PDFs. For supplier audits, diligence and inspection prep.
Sites
Palo Alto, California
One Form 483 · 2026 · 2 observations
Latest: Form 483, Mar 6, 2026 →
Documents
1 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2026-03-06 | 483 Form 483 | Palo Alto, California | 2 | $99 |
Investigators on these documents
FEI number 3022069968 · most recent document Mar 6, 2026
About Ascendis Pharma LLC
How many FDA Form 483s has Ascendis Pharma LLC received?
FDA Intel has 1 Form 483 on file for Ascendis Pharma LLC; the most recent is dated Mar 6, 2026.
When was Ascendis Pharma LLC last inspected by FDA?
The most recent FDA inspection document on file for Ascendis Pharma LLC is a Form 483 dated Mar 6, 2026, for the site in Palo Alto, California.
What did FDA cite at Ascendis Pharma LLC?
The regulations cited most in the observations on file for Ascendis Pharma LLC are 21 CFR 314.80(c)(1)(i) (Postmarketing reporting of adverse drug experiences), 1 time; 21 CFR 600.80(b) (Postmarketing reporting of adverse experiences), 1 time.